浏览全部资源
扫码关注微信
1.成都中医药大学,成都 610075
2.成都中医药大学 附属医院,成都 610072
[第一作者] 张美恒,在读硕士,从事皮肤病的临床及实验研究,E-mail: 395567429@qq.com
*郭静,博士,教授,从事皮肤病的临床及实验研究,E-mail: 80620404@qq.com
纸质出版日期:2020-05-05,
网络出版日期:2019-12-07,
收稿日期:2019-09-27,
扫 描 看 全 文
张美恒, 曾进浩, 徐风, 等. 基于IL-23/IL-17炎症轴探讨玉屏风颗粒治疗CU大鼠的效应机制[J]. 中国实验方剂学杂志, 2020,26(9):36-42.
Mei-heng ZHANG, Jin-hao ZENG, Feng XU, et al. Mechanism of Yupingfeng Granule on CU Rats Based on IL-23/IL-17 Inflammation Axis[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020,26(9):36-42.
张美恒, 曾进浩, 徐风, 等. 基于IL-23/IL-17炎症轴探讨玉屏风颗粒治疗CU大鼠的效应机制[J]. 中国实验方剂学杂志, 2020,26(9):36-42. DOI: 10.13422/j.cnki.syfjx.20200606.
Mei-heng ZHANG, Jin-hao ZENG, Feng XU, et al. Mechanism of Yupingfeng Granule on CU Rats Based on IL-23/IL-17 Inflammation Axis[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020,26(9):36-42. DOI: 10.13422/j.cnki.syfjx.20200606.
目的:
2
研究玉屏风颗粒对慢性荨麻疹(CU)大鼠皮肤肥大细胞脱颗粒的影响及白细胞介素-23(IL-23),白细胞介素-17(IL-17)炎症轴的干预机制。
方法:
2
选用SPF级SD大鼠,取60只随机分为正常组,模型组,氯雷他定组(0.9 mg·kg
-1
·d
-1
),玉屏风颗粒高、中、剂量组(4.05,2.7,1.35 g·kg
-1
·d
-1
)。运用腹腔注射卵白蛋白与氢氧化铝悬液和百白破疫苗进行致敏复制CU大鼠模型。苏木素-伊红(HE)染色观察大鼠皮肤组织病理学改变;甲苯胺蓝染色观察大鼠皮肤组织肥大细胞脱颗粒现象;免疫组化(IHC)检测皮肤组织IL-23,IL-17蛋白表达;采用实时荧光定量聚合酶链式反应(Real-time PCR)法检测皮肤组织IL-23,IL-17 mRNA转录水平。
结果:
2
玉屏风颗粒可显著改善CU大鼠皮肤真皮水肿、胶原束距离增宽、炎性细胞浸润等病理表现,同时可减轻CU大鼠皮肤组织肥大细胞脱颗粒反应。与正常组比较,模型组CU大鼠皮肤的IL-23,IL-17 mRNA水平及蛋白表达评分均明显增加(
P
<
0.05,
P
<
0.01);与模型组比较,玉屏风颗粒能显著下调CU大鼠皮肤的IL-23 mRNA水平及蛋白表达评分(
P
<
0.05,
P
<
0.01),以高剂量组疗效最佳;玉屏风颗粒对IL-17无显著调控作用。
结论:
2
玉屏风颗粒可显著减轻CU大鼠皮肤组织肥大细胞脱颗粒,改善真皮水肿、浆液性渗出、炎性细胞浸润等病理表现,其机制可能与其抑制IL-23促炎细胞因子分泌而改善CU病变有关。
Objective:
2
To study the effect of Yupingfeng granule on the degranulation of skin mast cells in chronic urticaria (CU) rats and the intervention mechanism of interleukin-23(IL-23)
interleukin-17(IL-17) inflammation axis.
Method:
2
Totally 60 SPF SD rats were selected and randomly divided into normal group (normal saline)
model group (normal saline)
and loratadine group (0.9 mg·kg
-1
·d
-1
)
high-dose Yupingfeng granules group (4.05 g·kg
-1
·d
-1
)
middle-dose group (2.7 g·kg
-1
·d
-1
)
low-dose group (1.35 g·kg
-1
·d
-1
). The CU rat model was reproduced through intraperitoneal injection of ovalbumin with aluminum hydroxide suspension and DTP vaccine. Histopathological changes of rat skin were observed by hematoxylin-eosin (HE) staining. Degranulation of mast cells in rat skin was determined by toluidine blue staining. IL-23 and IL-17 protein expressions in skin tissue were determined by immunohistochemistry (IHC). IL-23 and IL-17 mRNA transcription levels in skin tissue were determined by real-time fluorescence quantitative polymerase chain reaction (Real-time PCR).
Result:
2
Yupingfeng granules can significantly alleviate the pathological manifestations of dermal edema
collagen beam distance
inflammatory cell infiltration of CU rats
and reduce the degranulation reaction of skin tissue mast cells in CU rats. The IL-23
IL-17 mRNA and protein expressions of the skin of model group were significantly increased compared with the normal group (
P
<
0.05
P
<
0.01). Compared with the model group
Yupingfeng granules can significantly down-regulate IL-23 mRNA and protein expressions of CU rats (
P
<
0.05
P
<
0.01). Yupingfeng granules had no significant regulatory effect on IL-17.
Conclusion:
2
Yupingfeng granule can significantly reduce the degranulation of mast cells in skin tissue of CU rats
and improve the pathological manifestations
such as dermal edema
serous exudation and inflammatory cell infiltration. The mechanism may be related to inhibiting the secretion of IL-23 pro-inflammatory cytokines and improving CU lesions.
玉屏风颗粒慢性荨麻疹肥大细胞脱颗粒白细胞介素-23(IL-23)IL-17
Yupingfeng granulechronic urticariamast cell degranulationinterleukin-23(IL-23)IL-17
A LEZNOFF. urticaria and angioedema [J].Asian Pac J Allergy Immunol,2012,2(2):272.
T ZUBERBIER, R ASERO, C BINDSLEV-JENSEN, et al.EAACI/GA2LEN/EDF/WAO guideline:definition,classification and diagnosis of urticaria[J].Allergy,2009,61(3):1417-1426.
X HUANG, Z LI, R SUN.Synergistic actions of histamine-releasing factor and histamine releasing factor-reactive Ig E in chronic urticaria[J].Int Arch Allergy Immunol,2017,172(1):27-32.
C SACKESEN, B E SEKEREL, F ORHAN, et al.The etiology of different forms of urticaria in childhood[J].Pediatr Dermatol,2004,21(2):102-108.
孙诗黠,何文丽.慢性自发性荨麻疹发病机制及治疗研究进展[J].西南国防医药,2017,27(10):1141-1143.
陈甜甜.药物敷脐疗法联合当归饮子治疗血虚风燥型慢性荨麻疹临床疗效观察[D].成都:成都中医药大学,2018.
梁绮敏.加味玉屏风治疗慢性荨麻疹表虚不固证的临床效果[J].中国医药科学,2017,7(3):74-76.
曾文军,王柳均,徐彦春,等.玉屏风散加味方联合咪唑斯汀治疗慢性荨麻疹临床观察[J].现代中西医结合杂志,2006,17(21):2883-2884
赵春华,金艺,钱晓莺,等.枸地氯雷他定联合玉屏风颗粒治疗慢性荨麻疹疗效观察[J].上海中医药杂志,2017,51(9):74-77.
孙彬,刘文珊,李宏坤.中药调节慢性荨麻疹免疫机制的研究进展[J].中国实验方剂学杂志,2019,25(22):206-211.
M FERRER, E LUQUIN, A SANCHEZ-IHARROLA, et al.Secretion of cytokines,histamine and leukotrienes in chronic urticaria[J].Int Arch Allergy Immunol,2002,129(3):254-260.
毛长智,何俊慧,李冬梅.拟黑多刺蚁活性组分对系统性红斑狼疮的治疗作用及机制[J].中国实验方剂学杂志,2019,25(18):65-70.
L L REBER, N FROSSARD.Targeting mast cells in inflammatory diseases[J].Pharmacol Ther,2014,142:416-435.
G GRI, S PICONESE, B FROSSI, et a1.CD4”CD25+regulatory T cells suppress mast cell degranulation and allergic responses throush OX40-OX40L interaction[J].Immunity,2008,29(5):771-781.
M TAHERIAN, A R RAZAVI, M IZAD, et al.The role of interleukin-23 in stability of in vitro T helper-17 cells[J].Iran J Allergy Asthma Immunol,2014,13(2):131-137.
P MIOSSEC, T KORN, V K KUCHROO.Interleukin-17 and type17 helper T cells[J].N Eng J Med,2009,361(9):888-898.
E Z DA SILVA, M C JAMUR, C OLIVER. Mast cell function: a new vision of an old cell[J].J Histochem Cytochem,2014,62(10): 698-738.
J C DOS SANTOS, M H AZOR, V Y NOJIMA, et al.Increasedcirculating pro-inflammatory cytokines and imbalancedregulatory T-cell cytokines production in chronic idiopath-ic urticaria [J].Int Immunopharmacol,2008,8(10):1433-1440.
A DASCHNER, M RODERO, C DE FRUTOS, et al.Differentserum cytokine levels in chronic vs.acute Anisakis sim-plex sensitization-associated urticaria[J].Parasite Immunol,2011,33(6):357-362.
沈斌,冷建杭,王克义,等.慢性特发性荨麻疹患者外周血调节性T细胞和IL-17水平的研究[J].中华皮肤科杂志,2010,43(12):871-872.
T KOM, E BETTELLI, M OUKKA, et al.IL-17 and Thl7 cells [J].Annu Rev Immunol,2009,27,485-517.
何沅莉,单葵,曹雨微,等.慢性荨麻疹患者血清IL-17,IL-23 TGF-β水平检测分析[J].现代医药卫生,2018,34(3):364-365,368.
W LIN, Q ZHOU, C LIU, et al.Increased plasma IL-17,IL-31,and IL-33 levels in chronic spontaneous urticaria[J].Sci Rep,2017,7(1):17797.
郭敏,彭丽,郭静.当归饮子对慢性荨麻疹小鼠外周血清IL-17、IL-23水平的抑制作用[J].中华中医药杂志,2017,32(9):4121-4123
国家食品药品监督管理局.《中药、天然药物免疫毒性(过敏性、光过敏反应)研究的技术指导原则》[S].北京:国家食品药品监督管理局,2005.
陈文培,张子扬,周成浩,等.大鼠被动皮肤过敏反应实验条件的优化[J].中国药理学与毒理学杂志,2016,30(7):747-753.
苗明三,温亚娟,曹利华.瘙痒动物模型制备规范(草案)[J].中华中医药杂志,2018,33(2):610-613.
江小燕,王慧珠,桂黎黎,等.升麻素通过调节2型细胞因子抑制过敏性炎症[J].中国药理与临床,2014,30(2):28-30.
郑伟,灏覃,骊兰,等.过敏煎及其单味药抗过敏作用的实验研究进展[J].中国实验方剂学杂志,2019,25(17):194-201.
M E WALKER, J K HATFIELD, M A BROWN.New insights into the role of mast cells in autoimmunity:evidence for a common mechanism of action?[J].Biochim Biophys Acta,2012,1822(1):57-65.
Y XU, G CHEN.Mast cell and autoimmune diseases[J].Mediators Inflamm,2015,doi:10.1155/2015/246126http://dx.doi.org/10.1155/2015/246126.
C XU, K HAO, L YU, et al.Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer[J].Biomarkers,2014,19(4):287-290.
李瑞祥,梁碧华,杨婧,等.慢性自发性荨麻疹患者血清IL-17、IL-23水平的检测及意义[J].皮肤性病诊疗学杂志,2013,20(1):19-21.
张杰,窦侠,邵勇,等.IL-17/IL-23炎症轴在慢性自发性荨麻疹中的表达及临床意义[J].皮肤性病诊疗学杂志,2015,22(2):102-104.
0
浏览量
14
下载量
5
CSCD
关联资源
相关文章
相关作者
相关机构